TY - JOUR T1 - CPAP treatment increases anxiety in coronary artery disease patients with nonsleepy obstructive sleep apnoea: The RICCADSA randomized controlled trial JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.2497 VL - 56 IS - suppl 64 SP - 2497 AU - Yeliz Celik AU - Erik Thunström AU - Patrick J Strollo AU - Yüksel Peker Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/2497.abstract N2 - Background: Revascularization is related with increased anxiety in coronary artery disease (CAD). Impact of obstructive sleep apnoea (OSA) as well as treatment with continuous positive airway pressure (CPAP) on anxiety in cardiac cohorts is unknown.Aims and Objective: We explored the state of anxiety after CPAP therapy in CAD patients with nonsleepy OSA.Methods: This was one of the secondary outcomes of the RICCADSA randomized controlled trial, conducted in Sweden between 2005 and 2013. In all, 237 adults with nonsleepy OSA (apnea-hypopnea index ≥15/h, and Epworth Sleepiness Scale <10) who filled the Zung Self-rating Anxiety Scale (SAS) were included. Participants were assigned to CPAP (n=119), or no-CPAP (n=118). Between-group difference in absolute change on the SAS scores after 3- and 12 months of CPAP therapy was examined.Results: Intention-to-treat analysis showed no significant difference between the CPAP and no-CPAP groups. Notwithstanding, there was an increase in the median score (+3.75 points) after 3 months in the group using the device at least 3 hrs/night, while there was a decline (-1.25 points) in the non-adherent/no-CPAP group (p=0.01). The increase in the SAS score (+1.25 points) in the adherent group and the decline (-1.25 points) in the non-adherent/no-CPAP group remained significant after one year (p=0.04). In a multivariate linear regression model, there was an association between the increase in the SAS scores and CPAP hrs/night (β coefficient =0.14 [95% CI 0.00-0.69], p=0.05).Conclusions: CPAP treatment increases anxiety in revascularized CAD patients with nonsleepy OSA.Clinical trial registration: NCT00519597FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2497.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -